What is the difference between Cluster Headache (CH) and Migraine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Cluster headaches and migraines are two distinct primary headache disorders with different clinical characteristics.

Key Differences

  • Cluster headaches are typically marked by severe, unilateral orbital or periorbital pain lasting 15-180 minutes, often accompanied by ipsilateral cranial autonomic symptoms, such as conjunctival injection, lacrimation, and nasal congestion 1.
  • In contrast, migraines are characterized by moderate to severe, often unilateral, throbbing headaches lasting 4-72 hours 1.

Clinical Features

  • Cluster headaches affect ~0.1% of the general population and are highly characteristic, with frequently recurrent but short-lasting attacks 1.
  • Migraines, on the other hand, are more prevalent and can be accompanied by symptoms such as aura, photophobia, and phonophobia, which are not typically seen in cluster headaches.

Diagnosis and Management

  • A differential diagnosis is crucial to distinguish between cluster headaches, migraines, and other primary and secondary headache disorders, such as tension-type headache and medication-overuse headache 1.
  • Accurate diagnosis is essential for effective management, as treatment options vary significantly between these conditions, with cluster headaches often requiring high-flow oxygen or triptans, and migraines frequently managed with triptans, ergotamines, and preventative medications.

From the Research

Differences between Cluster Headache (CH) and Migraine

  • Cluster headache and migraine are regarded as distinct primary headaches, differing in multiple aspects such as gender-related and headache specific features (e.g., attack duration and frequency) 2
  • Cluster headache is characterized by severe unilateral orbital, supraorbital, and/or temporal pain, lasting from 15 to 180 minutes if untreated, associated with at least one of various autonomic symptoms during the headache 3
  • Migraine, on the other hand, is often characterized by nausea, vomiting, photophobia, and phonophobia, although some cluster headache patients may also experience these symptoms 4

Similarities between Cluster Headache (CH) and Migraine

  • Both cluster headache and migraine show clinical similarities in trigger factors (e.g., alcohol) and treatment response (e.g., triptans) 2
  • Some patients with cluster headache may experience migrainous aura preceding the attacks, and a large number of cluster headache patients do not receive adequate treatments 4

Treatment of Cluster Headache (CH)

  • Triptans, such as sumatriptan by injection, high flow 100 % oxygen by face mask, or non-invasive vagus nerve stimulation, are mainstay acute treatments of attacks of cluster headache 5
  • Interim preventive treatments to reduce attack frequency include a short course of high dose oral corticosteroids, local anesthetic/corticosteroid injection around the homolateral greater occipital nerve or the CGRP monoclonal antibody galcanezumab 5
  • Verapamil is considered the mainstay medium to long-term preventive with additional options being lithium, melatonin, topiramate, or non-invasive and invasive neuromodulation 5

Recent Advances in Cluster Headache (CH)

  • Recent advances have introduced effective treatments and broadened understanding of the clinical features of cluster headache, including the introduction of galcanezumab, a monoclonal antibody targeting CGRP, as the first specific preventive treatment for episodic cluster headache 6
  • International collaborations have led to identification of eight genetic loci associated with cluster headache, and targeting the trigeminal autonomic reflex by neurostimulation, or targeting the neuropeptide calcitonin gene-related peptide (CGRP), might lessen the attack burden 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.